In re Lucas QQ
Opinion of the Court
OPINION OF THE COURT
Appeal from an order of the Supreme Court (Guy, J.), entered November 12, 2015 in Broome County, which granted petitioner’s application, in a proceeding pursuant to Mental Hygiene Law article 33, to authorize petitioner to administer antipsy-chotic and other medications to respondent.
On October 1, 2015, respondent, a 24-year-old graduate student, was involuntarily admitted to the Greater Bingham-ton Health Center (hereinafter GBHC), a psychiatric hospital operated by the Office of Mental Health (hereinafter OMH) (see Mental Hygiene Law §§ 7.17, 9.37). Respondent had not previously been treated for a mental illness on either an inpatient or outpatient basis. Respondent’s treating psychiatrist at GBHC, Bernardo Izaguirre, diagnosed him with “[u]nspecified schizophrenia spectrum disorder” and prescribed a course of antipsychotic and other medications, which respondent refused to take. As a result, petitioner, GBHC’s acting clinical director, commenced this proceeding pursuant to Mental Hygiene Law article 33 on October 29, 2015, seeking an order permitting involuntary treatment. The petition was supported by the affidavit of Izaguirre and a reviewing psychiatrist, Xiaoying Chang.
A hearing was held on November 2, 2015, in which respondent declined the representation offered by counsel from Mental Hygiene Legal Service and opted to represent himself. Only Izaguirre and respondent testified. We take note that during respondent’s cross-examination of Izaguirre, as well as respondent’s direct testimony, respondent exhibited a coherent understanding in challenging the medication treatment plan as overbroad. At the close of proof, Supreme Court granted the petition. Three days later, the court issued an order that authorized petitioner, and any facility to which respondent might be transferred, to administer an extensive list of medications and to obtain respondent’s past psychiatric and medical records as needed to facilitate his treatment. Respondent was discharged from GBCH on December 21, 2015, shortly after filing a notice of appeal.
The threshold question is whether the appeal has been rendered moot given respondent’s release and the expiration of
As to whether a substantial and novel issue has been presented, we fully recognize that the governing standard has been in place since the Court of Appeals decision in Rivers v Katz (67 NY2d at 497-498). The state is authorized to administer medication against a patient’s wishes when it establishes by clear and convincing evidence that the patient lacks “the capacity to make a reasoned decision with respect to proposed treatment,” and “the proposed treatment is narrowly tailored to give substantive effect to the patient’s liberty interest, taking into consideration all relevant circumstances, including the patient’s best interests, the benefits to be gained from the treatment, the adverse side effects associated with the treatment and any less intrusive alternative treatments” (id. at 497). Whether a patient lacks such capacity presents a question of fact for the trial court to address (see Matter of Jay S. [Barber], 118 AD3d 803, 804 [2014]; Matter of Joseph O., 245 AD2d 856, 856 [1997]). What we find significant and novel here is how that standard is to be met by a petitioner and applied by the trial court with respect to the formulation of a medication treatment plan, and, for that reason, we will address the merits of the appeal (see Mental Hygiene Legal Servs. v Ford, 92 NY2d 500, 505-506 [1998]; Matter of Anthony H [Karpati], 82 AD3d 1240, 1241 [2011], lv denied 17 NY3d 708 [2011]).
This point implicates the secondary problem presented in that Supreme Court failed to make specific findings on the record as to respondent’s capacity and the viability of the treatment plan. Instead, the court stated that it was granting the petition “based on what . . . Izaguirre has testified to.” The clear and convincing standard that governs these types of proceedings demands more. For his part, Izaguirre did not explain the basis for the medications listed in his treatment proposal. To the contrary, he testified that only one medication, Risperdal, had been recommended at that point. Moreover, the court cannot, as it did here, rely on testimony from other cases that the provider will “request some flexibility” in formulating a treatment plan. The problem is further compounded by the fact that Izaguirre testified that respondent lacked insight into his mental illness and had poor judgment for refusing to take the medications listed on what was indisputably an overbroad treatment plan. Given the pervasive flaw in the medication treatment plan, we agree with respondent that petitioner failed to meet its burden of proof in this case.
There are two additional components of the final order that warrant comment. Despite the fact that petitioner made no request for such relief and that respondent was given no advance notice, Supreme Court authorized GBHC to “obtain any of [respondent’s] past psychiatric/medical records” and authorized the treatment at “any other medical/psychiatric facility [respondent’s] care may require” — an authorization the
Ordered that the order is reversed, on the law, without costs, and petition dismissed.
Case-law data current through December 31, 2025. Source: CourtListener bulk data.